Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-3

Basically this was a fully taxpayer-funded venture last quarter. Outrageous really.

And I wonder when the Akili deal was actually terminated - that should’ve been announced to market well before now, regardless of the share price having practically no further room left to drop. They cannot act like they only terminated this last night. The Akili licensing was supposed to be TALi’s big break into the US and, as you allude to, it’s not at all clear where in the preparatory process for FDA approval this product even got to, and whether any of that work is accessible to the Aus business and salvageable or not.

TALi, the rusted out ghost ship of the digital seas.